Our Associate Director of Analytical Development, Christopher Warner, PhD, presented a scientific poster at the 5th Annual Novel Conjugates Summit in Boston (March 9–11). The poster highlighted an approach to ncAA-enabled site-specific conjugation without sacrificing yield, achieving ~15 g/L VHH titers with 100% pAzF incorporation and 100% click conversion at pre-production scale. Because ncAA adoption is often limited by toxicity and reduced yields at fermentation scale, this work points toward scalable production of site-specific bioconjugates such as next-generation ADCs.
